- |||||||||| Lodonal (naltrexone low dose oral) / Transparency Life Sciences
Review, Journal: The Uses of Naltrexone in Dermatological Conditions. (Pubmed Central) - Oct 29, 2019
Data suggest that naltrexone could be helpful in the treatment of pruritus and a variety of inflammatory and acantholytic skin diseases that are refractory to other treatments. At higher doses, liver function tests should be monitored on a periodic basis.
- |||||||||| Lodonal (naltrexone low dose oral) / Transparency Life Sciences
Review, Journal: Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions: A Systematic Review. (Pubmed Central) - Oct 18, 2019
The findings suggest that low-dose naltrexone is safe and effective in the treatment of Hailey-Hailey disease and lichen planopilaris and both low- and high-dose naltrexone successfully treat pruritus attributable to various pathologic conditions; however, more adverse effects occurred in those taking high doses. Low-dose naltrexone has the potential for the treatment of chronic inflammatory skin conditions; however, additional evidence is needed for dosing and long-term treatment guidelines.
- |||||||||| Contrave (naltrexone + bupropion) / Orexigen, Lodonal (naltrexone low dose oral) / Transparency Life Sciences
Preclinical, Journal: Co-administration of low-dose naltrexone and bupropion reduces alcohol drinking in alcohol-preferring (P) rats. (Pubmed Central) - Sep 20, 2019
A reduction in side effects can facilitate patient compliance and improve clinical outcomes for alcoholics and heavy drinkers who want to reduce their alcohol intake. The results, together with those from our prior studies, demonstrate the strength of a combinatorial pharmacotherapeutic approach to the treatment of alcohol use disorder.
- |||||||||| Lodonal (naltrexone low dose oral) / Transparency Life Sciences
Journal: Intermittent blockade of OGFr and treatment of autoimmune disorders. (Pubmed Central) - Sep 20, 2019
This mini-review presents information on the intermittent blockade of the opioid growth factor (OGF)-OGF receptor (OGFr) axis by low-dose naltrexone (LDN), and the role of enkephalin (i.e. OGF) in autoimmune disorders, specifically multiple sclerosis, Crohn's, and fibromyalgia...Intermittent OGFr blockade with LDN restores serum enkephalin levels that correlate with reduced behavioral and pathological signs of EAE; LDN also increases enkephalin levels in naïve mice. The interplay between LDN, and the onset and treatment of autoimmune diseases, chronic pain, and other addictive behaviors requires further investigation, but highlights a central role for enkephalins and intermittent blockade of the OGF-OGFr pathway in pathogenesis and treatment of these disorders.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion date, Trial primary completion date: LoDoNaVasc: Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis (clinicaltrials.gov) - Sep 12, 2019
P2, N=60, Recruiting,
The interplay between LDN, and the onset and treatment of autoimmune diseases, chronic pain, and other addictive behaviors requires further investigation, but highlights a central role for enkephalins and intermittent blockade of the OGF-OGFr pathway in pathogenesis and treatment of these disorders. Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Aug 2019 --> Aug 2020
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion date, Trial primary completion date: Immune Effects of Low-dose Naltrexone in ME/CFS (clinicaltrials.gov) - Sep 6, 2019
P=N/A, N=30, Suspended,
No abstract available Trial completion date: Aug 2019 --> Aug 2020 | Trial primary completion date: Aug 2019 --> Aug 2020
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion date, Trial primary completion date: LDN-VA: Low Dose Naltrexone for Chronic Pain From Arthritis (clinicaltrials.gov) - Aug 28, 2019
P2, N=60, Recruiting,
Trial completion date: Aug 2019 --> Aug 2020 | Trial primary completion date: Aug 2019 --> Aug 2020 Trial completion date: Sep 2019 --> Dec 2019 | Trial primary completion date: Sep 2019 --> Dec 2019
- |||||||||| Lodonal (naltrexone low dose oral) / Transparency Life Sciences
Journal: Low Dose Naltrexone in Dermatology (Pubmed Central) - Jul 19, 2019
J Drugs Dermatol. 2019;18(3):235-238.
- |||||||||| Lodonal (naltrexone low dose oral) / Transparency Life Sciences
Clinical, Journal: Low dose Naltrexone for induction of remission in inflammatory bowel disease patients. (Pubmed Central) - Jul 11, 2019
Naltrexone directly improves epithelial barrier function by improving wound healing and reducing mucosal ER stress levels. Low dose Naltrexone treatment is effective and safe, and could be considered for the treatment of therapy refractory IBD patients.
- |||||||||| Lodonal (naltrexone low dose oral) / Transparency Life Sciences
Review, Journal: Psychoneuroimmunological approach to gastrointestinal related pain. (Pubmed Central) - Mar 27, 2019
These disease modulating add-ons include probiotics, prebiotics, food supplements with anti-inflammatory properties, various forms of psychotherapy, and low-dose naltrexone as a glial modulator that attenuates neuroinflammation. Clearly, a broader and still under exploited set of evidence-based tools is available for clinical use.
- |||||||||| carboplatin / generics
Journal, HEOR: The effect of naltrexone as a carboplatin chemotherapy-associated drug on the immune response, quality of life and survival of dogs with mammary carcinoma. (Pubmed Central) - Mar 25, 2019
The objective of this study was to evaluate the effect of low-dose naltrexone (LDN) as a carboplatin chemotherapy-associated drug in female dogs with mammary carcinoma in benign mixed tumors (MC-BMT) after mastectomy and to assess its association with quality of life and survival rates...All animals were subjected to clinical evaluation, mastectomy, peripheral blood lymphocyte immunophenotyping, beta-endorphin and met-enkephalin quantification, and evaluation of survival rates and quality of life scores...Evaluation of clinical and pathological parameters indicated a significant association between the use of LDN and both prolonged survival and enhanced quality of life. These results indicate that LDN is a viable chemotherapy-associated treatment in female dogs with MC-BMT, maintaining their quality of life and prolonging survival rates.
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment open, Trial completion date, Trial primary completion date: LoDoNaVasc: Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis (clinicaltrials.gov) - Feb 12, 2019
P2, N=60, Recruiting,
These results indicate that LDN is a viable chemotherapy-associated treatment in female dogs with MC-BMT, maintaining their quality of life and prolonging survival rates. Not yet recruiting --> Recruiting | Trial completion date: Aug 2019 --> Dec 2019 | Trial primary completion date: May 2019 --> Aug 2019
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion, Enrollment change: PETER-PAIN: St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene (clinicaltrials.gov) - Jan 18, 2019
P1/2, N=11, Completed,
Not yet recruiting --> Recruiting | Trial completion date: Aug 2019 --> Dec 2019 | Trial primary completion date: May 2019 --> Aug 2019 Recruiting --> Completed | N=16 --> 11
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion date, Trial primary completion date: LDN-VA: Low Dose Naltrexone for Chronic Pain From Arthritis (clinicaltrials.gov) - Oct 22, 2018
P2, N=60, Recruiting,
Recruiting --> Completed | N=16 --> 11 Trial completion date: Jun 2019 --> Sep 2019 | Trial primary completion date: Jun 2019 --> Sep 2019
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial primary completion date: Immune Effects of Low-dose Naltrexone in ME/CFS (clinicaltrials.gov) - Sep 19, 2018
P=N/A, N=30, Suspended,
Initiation date: Sep 2018 --> Dec 2018 Trial primary completion date: Aug 2018 --> Aug 2019
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial completion date, Trial initiation date, Trial primary completion date: LDN-VA: Low Dose Naltrexone for Chronic Pain From Arthritis (clinicaltrials.gov) - Feb 6, 2018
P2, N=60, Not yet recruiting,
Trial primary completion date: Jun 2017 --> Jun 2019 Initiation date: Nov 2017 --> Mar 2018 | Trial completion date: Mar 2019 --> Jun 2019 | Trial primary completion date: Mar 2019 --> Jun 2019
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial initiation date, Trial primary completion date: PETER-PAIN: St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene (clinicaltrials.gov) - Jan 26, 2018
P1/2, N=16, Not yet recruiting,
Initiation date: Nov 2017 --> Mar 2018 | Trial completion date: Mar 2019 --> Jun 2019 | Trial primary completion date: Mar 2019 --> Jun 2019 Initiation date: Dec 2017 --> Jun 2018 | Trial primary completion date: Jul 2018 --> Feb 2019
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial initiation date: LDN-VA: Low Dose Naltrexone for Chronic Pain From Arthritis (clinicaltrials.gov) - Aug 23, 2017
P2, N=60, Not yet recruiting,
Initiation date: Dec 2017 --> Jun 2018 | Trial primary completion date: Jul 2018 --> Feb 2019 Initiation date: Jul 2017 --> Nov 2017
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial initiation date: LDN-VA: Low Dose Naltrexone for Chronic Pain From Arthritis (clinicaltrials.gov) - May 30, 2017
P2, N=60, Not yet recruiting,
Initiation date: Jul 2017 --> Nov 2017 Initiation date: Feb 2017 --> Jul 2017
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Trial suspension: Immune Effects of Low-dose Naltrexone in ME/CFS (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=30, Suspended,
Active, not recruiting --> Completed | N=150 --> 111 Recruiting --> Suspended
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment open, Trial initiation date: Immune Effects of Low-dose Naltrexone in ME/CFS (clinicaltrials.gov) - Jan 17, 2017
P=N/A, N=30, Recruiting,
Recruiting --> Suspended Not yet recruiting --> Recruiting | Initiation date: Nov 2016 --> Jan 2016
|
